Revolution Medicines (RVMD) Senior Advisor Stephen Kelsey Sells Shares

What Happened
Stephen Kelsey, Senior Advisor to the CEO of Revolution Medicines (RVMD), exercised stock options for a total of 92,531 shares (52,500 at $42.45 and 40,031 at $40.74) at a combined exercise cost of about $3.86M, and on Sept 11, 2026 sold 92,531 shares in multiple open-market trades for roughly $22.6M in proceeds. The filing shows the option exercises and the same-day sales — effectively an exercise followed by sale (cashless/offset sale).

Key Details

• Transaction date: September 11, 2026 (Form 4 filed September 15, 2026). Filing appears timely (reported within the typical 2-business-day Form 4 window).
• Options exercised: 52,500 shares @ $42.45 ($2,228,625) and 40,031 shares @ $40.74 ($1,630,863) — total cost ≈ $3.86M.
• Shares sold: 92,531 shares via multiple open-market trades; aggregate proceeds ≈ $22,584,255.
• Sale price execution: trades executed in multiple blocks with reported weighted-average prices and ranges across trades (overall trade prices ranged roughly $198.35 to $206.05 per share across the blocks).
• Holdings note: filing references 76,251 restricted stock units as part of holdings (footnote F10). The total shares owned after these transactions is not specified in the provided excerpt.
• Notable footnotes: sales were made pursuant to a 10b5-1 trading plan adopted June 12, 2026 (F1). Several footnotes (F2–F9) detail that the open-market sales were executed in multiple trades at price ranges and the filer will provide per-trade breakdown on request. Vesting/option notes appear in the filing (F11 fully vested; F12 describes monthly vesting schedule for other option grants).

Context
This was an option exercise followed by same-day sales — a routine insider action used to exercise and liquidate option shares (often to cover exercise cost/taxes or to diversify). The presence of a 10b5-1 trading plan indicates the sales were pre-planned and executed under that plan. The filing is factual and does not state motives.